This study is looking at how well ravulizumab works in people with neuromyelitis optica spectrum disorder (NMOSD), a condition that affects the brain and spinal cord. All participants will receive ravulizumab, a medication already approved for use, as part of their regular care. Researchers will compare how often participants have relapses (flare-ups of symptoms) before and after starting ravulizumab. They will also use MRI scans to see how the medication affects the brain and spinal cord, and look for signs of disease progression. You may be able to join if you are over 18, have aquaporin-4 IgG positive NMOSD, and are already being treated with ravulizumab. The study is currently recruiting about 35 participants.

Study design

This is an observational study, meaning researchers will watch how ravulizumab works in people receiving it as part of their regular care. It is a single-center study planning to enroll 35 participants.

What's involved

You would undergo a screening process for up to 45 days to confirm your eligibility. After enrollment, you will receive ravulizumab as prescribed by your doctor, consistent with its approved use.

Compensation

Not stated in the trial record.

Follow-up

The study will measure clinical relapses between 52 and 78 weeks after starting ravulizumab.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.